Linsitinib (OSI-906)

目录号：S1091

Linsitinib (OSI-906) Chemical Structure

Molecular Weight(MW): 421.49

Linsitinib (OSI-906)是一种选择性IGF-1R抑制剂，在无细胞试验中IC50为35 nM；对InsR抑制作用适中，IC50为75 nM，对Abl，ALK，BTK，EGFR， FGFR1/2，PKA等没有抑制活性。Phase 3。

规格 价格 库存 购买数量  
In DMSO RMB 1550.54 现货
RMB 1393.48 现货
RMB 2226.24 现货
RMB 5899.91 现货
有超大折扣
大剂量询单有大折扣！

今日订购，明日送达，全国免运费！

全国免费电话：400-668-6834   |   Email：info@selleck.cn

客户使用Selleck该产品发表文献78篇：

产品安全说明书

IGF-1R抑制剂选择性比较

生物活性

产品描述 Linsitinib (OSI-906)是一种选择性IGF-1R抑制剂，在无细胞试验中IC50为35 nM；对InsR抑制作用适中，IC50为75 nM，对Abl，ALK，BTK，EGFR， FGFR1/2，PKA等没有抑制活性。Phase 3。
靶点
IGF-1R [1]
(Cell-free assay)		 Insulin Receptor [1]
(Cell-free assay)		 IRR [1]
(Cell-free assay)
35 nM 75 nM 75 nM
体外研究

OSI-906 抑制IGF-IR自磷酸化和下游信号蛋白AKT, ERK1/2和S6激酶的激活，IC50为0.028到 0.13 μM。OSI-906通过与C-螺旋相互作用而使靶点蛋白形成中间结构形态。OSI-906作用于肝脏微粒体，具有良好的代谢稳定性。OSI-906浓度为1μM时，完全抑制IR 和IGF-IR磷酸化。OSI-906抑制一些肿瘤细胞系增殖，包括非小细胞肺癌和结肠直肠癌(CRC)肿瘤细胞系，EC50为0.021到 0.810 μM。[1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
A4-Fuk NV7nXnBoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn\TTWM2OD1yLkCyPFA3KM7:TR?= M2j6Z3NCVkeHUh?=
KS-1 M4TBT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYjJR|UxRTBwMEO4N|Uh|ryP NGGyelBUSU6JRWK=
TE-11 Mkn1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3\nRWlEPTB;MD6wO|gzOiEQvF2= MXLTRW5ITVJ?
EW-1 Mn;jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3j1fGlEPTB;MD6wPFU5PSEQvF2= NILJWHVUSU6JRWK=
HMV-II MnPFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2HyU2lEPTB;MD6wPFg1PiEQvF2= MWPTRW5ITVJ?
COLO-205 NU\aNohFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFmxNJRKSzVyPUCuNVA1PTRizszN M1zaT3NCVkeHUh?=
ES1 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mm\ZTWM2OD1yLkGwOlk3KM7:TR?= NV;mXlJSW0GQR1XS
GDM-1 Mom1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYnJR|UxRTBwMUO2O|Ih|ryP MnXrV2FPT0WU
ML-2 NUWzcGYyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXjJR|UxRTBwMUW4PVYh|ryP NGPLbWlUSU6JRWK=
Saos-2 NEjJVJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIHLXG5KSzVyPUCuNVY2OjZizszN Ml;yV2FPT0WU
NCI-H1355 Mn31S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVnJR|UxRTBwMUixN|Uh|ryP NXvnXFVlW0GQR1XS
G-401 M1HmVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWrMNmFlUUN3ME2wMlE5OjNizszN NHjTT4xUSU6JRWK=
EW-16 NIfU[45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX3MO3dYUUN3ME2wMlE5Pzd5IN88US=> M{DuSXNCVkeHUh?=
EW-7 NIPlVpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NY[wOZlkUUN3ME2wMlE5QDhzIN88US=> NUDsWW9HW0GQR1XS
NCI-H727 M2HW[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYLGUYd{UUN3ME2wMlE6Pzl2IN88US=> MWXTRW5ITVJ?
LCLC-97TM1 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M17HT2lEPTB;MD6yNFk2PSEQvF2= MnPhV2FPT0WU
NCI-H650 MnvZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MULJR|UxRTBwMkGzPFQh|ryP M2rpZnNCVkeHUh?=
NCI-H2122 M3\Xemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MU\JR|UxRTBwMkOyPVkh|ryP NH3rWYpUSU6JRWK=
SK-N-DZ MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkDOTWM2OD1yLkKzOlk5KM7:TR?= NYCyflJmW0GQR1XS
HT-29 M4LRWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHL6eXVKSzVyPUCuNlQzPDhizszN NF\oelVUSU6JRWK=
LB771-HNC NUXwS3FiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHm5RnVKSzVyPUCuNlU6OTVizszN M4rOUnNCVkeHUh?=
HT-144 M2Dne2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M125[2lEPTB;MD6yOlE6OSEQvF2= NVP3W3Y1W0GQR1XS
LAN-6 NGHOTI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4D6bWlEPTB;MD6yOlM1QCEQvF2= NUjBb2pRW0GQR1XS
EW-18 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGrJSFdKSzVyPUCuNlcxODFizszN MVXTRW5ITVJ?
LS-1034 MnTPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml7FTWM2OD1yLkK3NVMzKM7:TR?= MWHTRW5ITVJ?
EW-11 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWjJR|UxRTBwMki0N|Ih|ryP NEPsW2JUSU6JRWK=
SNU-C1 MmfDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXjjfWtwUUN3ME2wMlI6OzF|IN88US=> M3nndHNCVkeHUh?=
RS4-11 NX\nNmF5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2q5XWlEPTB;MD6zN|c2QCEQvF2= NIP5S4VUSU6JRWK=
ES4 M3vF[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX3HNFFyUUN3ME2wMlQyODN6IN88US=> NUnXU2kzW0GQR1XS
COLO-320-HSR NVO3OnR{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{XWS2lEPTB;MD60NVM3QCEQvF2= NGT5R21USU6JRWK=
NB10 NYDWZlF7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVTJR|UxRTBwNEW0N|ch|ryP MUHTRW5ITVJ?
BFTC-905 NUfNOXlXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1y0cWlEPTB;MD60Olc2QCEQvF2= MXnTRW5ITVJ?
A375 NF7WfmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NInz[WRKSzVyPUCuOFc3OTdizszN M{PlXXNCVkeHUh?=
SJRH30 NVH3bIVnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{HNUWlEPTB;MD61NFgzOiEQvF2= M1z2e3NCVkeHUh?=
NOS-1 NW[xWWZ2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{HN[mlEPTB;MD61NlI3PyEQvF2= Mon5V2FPT0WU
SIG-M5 M3\3VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIfXUJhKSzVyPUCuOVM2PTdizszN MkfYV2FPT0WU
DOK M1PURmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGHyTWpKSzVyPUCuOVU3KM7:TR?= MmXNV2FPT0WU
NB69 MmDiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHn0dWVKSzVyPUCuOVgzPTdizszN MWnTRW5ITVJ?
SK-NEP-1 M37Z[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2fiNmlEPTB;MD62NFI{PiEQvF2= NFvRfnNUSU6JRWK=
SK-MM-2 NGDZWJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn3rTWM2OD1yLk[1OFkyKM7:TR?= MYjTRW5ITVJ?
NCI-H358 MoDZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnXwTWM2OD1yLk[3NFgzKM7:TR?= NID3T49USU6JRWK=
RH-1 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmfKTWM2OD1yLke0PFU6KM7:TR?= MYXTRW5ITVJ?
NH-12 M{HiTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUDJR|UxRTBwN{[wOFYh|ryP MWDTRW5ITVJ?
TE-12 M2PVfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Moq5TWM2OD1yLke2OFg3KM7:TR?= MlPzV2FPT0WU
COLO-668 M{\sWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn\ITWM2OD1yLki0OlY3KM7:TR?= NVXEVnNQW0GQR1XS
PANC-08-13 M3LSbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2XoWGlEPTB;MD64OlM4PyEQvF2= M{H1[nNCVkeHUh?=
HCC2998 MnLLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3fiXGlEPTB;MD64PFI3OyEQvF2= NF;0SFBUSU6JRWK=
ABC-1 NVXsTYRET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGTiR4JKSzVyPUCuPVA{PTJizszN NVTiZm86W0GQR1XS
ES6 NF\FZW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUXJR|UxRTBwOUGwOlYh|ryP NV;DS5N6W0GQR1XS
SNU-387 M17kSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnXMTWM2OD1yLkm5N|k{KM7:TR?= NH7F[XJUSU6JRWK=
CMK MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmXtTWM2OD1yLkm5PVI6KM7:TR?= M17pfnNCVkeHUh?=
SJSA-1 M{Hj[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3rLS2lEPTB;MT6wN|Y2OyEQvF2= NGLT[JhUSU6JRWK=
SIMA MmDlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn\OTWM2OD1zLkC2PFI2KM7:TR?= MX\TRW5ITVJ?
ES3 M3\F[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlHsTWM2OD1zLkGyNlk4KM7:TR?= Mny5V2FPT0WU
IGROV-1 NIr6[GtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVPJR|UxRTFwMUW0OFQh|ryP Mnu1V2FPT0WU
MEL-JUSO MnS1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGHpeHZKSzVyPUGuNVU4PTlizszN MlvVV2FPT0WU
T84 MkDnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4nqdWlEPTB;MT6yNFkyPCEQvF2= NFjFNmFUSU6JRWK=
CAL-85-1 M3HvcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX\JR|UxRTFwMkOxN|gh|ryP NFvtbFRUSU6JRWK=
RD Mn[yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlWwTWM2OD1zLkK2OFU2KM7:TR?= NV3QcYtmW0GQR1XS
TE-8 MnXOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUHJR|UxRTFwM{G0OlIh|ryP NX20fmFHW0GQR1XS
L-363 NXPGSIlDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYHJR|UxRTFwM{SyNFgh|ryP MkKyV2FPT0WU
EKVX MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2rFO2lEPTB;MT6zOFU3QCEQvF2= MkjxV2FPT0WU
SK-MEL-3 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn;lTWM2OD1zLkS4OVU3KM7:TR?= MVvTRW5ITVJ?
TGBC24TKB NH;afXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYnDZ4twUUN3ME2xMlUxOTl|IN88US=> NG\KN41USU6JRWK=
NCI-H1770 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEe1SopKSzVyPUGuOVEyOTNizszN MY\TRW5ITVJ?
HuH-7 NIL0[JlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFzZbY9KSzVyPUGuOlAxQThizszN M1rBfHNCVkeHUh?=
HL-60 NGKzemdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUHJR|UxRTFwNk[5Nlgh|ryP NX:wXJJIW0GQR1XS
TE-1 M{HwXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUXifnZkUUN3ME2xMlcxQTR3IN88US=> MkPXV2FPT0WU
LC-2-ad M3zyT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{Ll[mlEPTB;MT63N|g5PyEQvF2= M3jNOXNCVkeHUh?=
LB647-SCLC MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGqye2RKSzVyPUGuO|Y2QDNizszN NYTXNFJjW0GQR1XS
NCI-H2171 M3PCSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFXLWmlKSzVyPUGuO|c4OTZizszN NHe2[49USU6JRWK=
SK-PN-DW MonyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHLseY9KSzVyPUGuPVEzQThizszN MWTTRW5ITVJ?
MC-IXC M4S4e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MY\JR|UxRTFwOUi5PEDPxE1? NYnpPFNnW0GQR1XS
LS-513 MmP6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHTCOVlKSzVyPUKuNFU{ODVizszN MYHTRW5ITVJ?
EW-3 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M13WfWlEPTB;Mj6wPVg1PCEQvF2= NGfVXYtUSU6JRWK=
OPM-2 NIHrcHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVjjTnh4UUN3ME2yMlExOiEQvF2= M4rrVHNCVkeHUh?=
LP-1 MkL2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFvuc4VKSzVyPUKuNlU5ODdizszN NYT4eFhqW0GQR1XS
LU-134-A NVLKNGw3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{jMZWlEPTB;Mj6yO|ch|ryP MYTTRW5ITVJ?
CP66-MEL M1rWcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlPLTWM2OD1{LkK5NFE1KM7:TR?= MnXNV2FPT0WU
HCC1143 NEnNTnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUTJR|UxRTJwNEWzOlgh|ryP NXnhXXdxW0GQR1XS
LOXIMVI MlXHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mmj3TWM2OD1{Lk[wNlEh|ryP NGLRcVJUSU6JRWK=
TE-10 M1nYdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYXvT3ZiUUN3ME2yMlcxQDN6IN88US=> NWG1cYE1W0GQR1XS
NCI-H1882 M4D2bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{DkRWlEPTB;Mj63OVIzPyEQvF2= Mk\PV2FPT0WU
CHP-126 NIXUc2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUXJR|UxRTJwN{[zNVch|ryP MVfTRW5ITVJ?
NCI-H1623 MljmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYTJR|UxRTJwOUKwNlQh|ryP NIDsW4xUSU6JRWK=
GB-1 NVOwW5dRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MULJR|UxRTJwOUO0NFQh|ryP MU\TRW5ITVJ?
RCC10RGB NXfY[Jd{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXHJb4t7UUN3ME2yMlk2OjhzIN88US=> MnziV2FPT0WU
NCI-H2141 MnzLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGTPRotKSzVyPUKuPVY5QTZizszN MnvxV2FPT0WU
GI-ME-N MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF7oeYFKSzVyPUOuNFA2PjVizszN M{LhbHNCVkeHUh?=
NCI-H526 MlO4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXXYdGliUUN3ME2zMlA1ODh3IN88US=> NFvG[IlUSU6JRWK=
NCI-H747 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWLJR|UxRTNwMES5PVIh|ryP MkfJV2FPT0WU
SNU-423 M1TVeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4LyVWlEPTB;Mz6yNFMyOyEQvF2= MkjXV2FPT0WU
A427 M2fKW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnvFTWM2OD1|LkK1Olk6KM7:TR?= MX;TRW5ITVJ?
CAL-12T M4C1U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4rkSmlEPTB;Mz60NFcyOyEQvF2= M1i0cXNCVkeHUh?=
LU-99A M2XmXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYjJR|UxRTNwNEexNFUh|ryP M{e5WHNCVkeHUh?=
MS-1 M4rCd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml\BTWM2OD1|LkWzOFI6KM7:TR?= MYHTRW5ITVJ?
SK-LU-1 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4jhZ2lEPTB;Mz63OlI6PSEQvF2= MmXqV2FPT0WU
SW837 NHXSTmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXfJR|UxRTNwN{[zN|Mh|ryP M3v5N3NCVkeHUh?=
ES8 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXjJR|UxRTNwOEO4O|ch|ryP M3W3Z3NCVkeHUh?=
MZ2-MEL MkTxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWHJR|UxRTNwOUKwPFYh|ryP NXflXlNSW0GQR1XS
TGW MoXZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnzJTWM2OD12LkCxN|EyKM7:TR?= M2rvbXNCVkeHUh?=
GP5d NV71V2doT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmPNTWM2OD12LkC1N|YzKM7:TR?= NGPKfHJUSU6JRWK=
BB49-HNC M33xcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIi4VnNKSzVyPUSuNVUzOTNizszN NGTDXIJUSU6JRWK=
NB13 MoDFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkjBTWM2OD12LkK2PFg4KM7:TR?= Mly3V2FPT0WU
NTERA-S-cl-D1 M1fnZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGDVUZVKSzVyPUSuNlg3OTVizszN M4TBU3NCVkeHUh?=
NCI-H1648 M1fPTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVOyVox4UUN3ME20MlI6QDF7IN88US=> NFW2U2NUSU6JRWK=
LCLC-103H M2X2T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXHoV4lsUUN3ME20MlMzOTl3IN88US=> Mn2zV2FPT0WU
LS-411N NH3ucYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml;2TWM2OD12LkS0PFg2KM7:TR?= NWLMN|VyW0GQR1XS
NCI-H1092 Mk\4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWLBd|B4UUN3ME20MlQ2Pjh5IN88US=> NEPoPWNUSU6JRWK=
PANC-10-05 NGHMd|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4W0RmlEPTB;ND62PVg1KM7:TR?= NXfVcG42W0GQR1XS
DK-MG M17ucGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGjBTZlKSzVyPUSuPFA6OzNizszN NFj1bmlUSU6JRWK=
OVCAR-5 M{fVZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2TLfWlEPTB;ND64NVIzPiEQvF2= MlHyV2FPT0WU
CAL-39 NVT2cY9LT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3:1N2lEPTB;ND64O|Y4KM7:TR?= MnnhV2FPT0WU
TE-441-T MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUDJR|UxRTRwOUC1N|ch|ryP MXPTRW5ITVJ?
MOLT-16 NELmfY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGnu[4NKSzVyPUSuPVUzPTNizszN NEPncIJUSU6JRWK=
MCF7 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXW3[W82UUN3ME21MlE1PTF5IN88US=> M1LEOXNCVkeHUh?=
CAPAN-1 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHvW[FFKSzVyPUWuNlU4ODdizszN NF2xUHVUSU6JRWK=
PSN1 MlnlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlvlTWM2OD13LkK3NlM2KM7:TR?= NVLlTIQ6W0GQR1XS
NCI-H292 M4jJ[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEjncVBKSzVyPUWuN|AxPDRizszN NEfydo9USU6JRWK=
CPC-N MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYDvTY54UUN3ME21MlM6PDF7IN88US=> MnLEV2FPT0WU
DoTc2-4510 M4e0WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2LUZWlEPTB;NT60OVM4OSEQvF2= MU\TRW5ITVJ?
LB1047-RCC NH3HV3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYTyUG57UUN3ME21MlU2QTN|IN88US=> Mn\wV2FPT0WU
MHH-ES-1 M4PjOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2SxUmlEPTB;NT61PVkxPyEQvF2= M3\VXnNCVkeHUh?=
NMC-G1 M176NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVLrZnJLUUN3ME21MlcxOjJ5IN88US=> M4fqfnNCVkeHUh?=
SW1710 M3fYR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{DXRWlEPTB;NT63OFc2OSEQvF2= NH74VZRUSU6JRWK=
YAPC M3nhZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NW\qVod6UUN3ME21Mlc3OjBzIN88US=> NInPSY9USU6JRWK=
22RV1 NFrPNXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWjJR|UxRTVwOECwNVkh|ryP M2XLbHNCVkeHUh?=
COLO-679 MnrYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIGzW5BKSzVyPUWuPFg6PDhizszN NXvsTIdLW0GQR1XS
TCCSUP MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3flNmlEPTB;NT65N|I2QSEQvF2= M{XRNnNCVkeHUh?=
C2BBe1 NFLEe4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHfHUoFKSzVyPUWuPVM6PyEQvF2= M{j2[3NCVkeHUh?=
TE-15 MoTLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUPJR|UxRTZwME[2NFUh|ryP MkfHV2FPT0WU
SCLC-21H NHTpVnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH;yOFZKSzVyPU[uNVA5PDNizszN Mnr4V2FPT0WU
EoL-1-cell NFf6PI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MY\JR|UxRTZwMU[1OlMh|ryP NGC3U|FUSU6JRWK=
NKM-1 Mk\BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX7JR|UxRTZwMU[3NUDPxE1? MVTTRW5ITVJ?
NCI-H1304 NWGxWZNVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFPW[4ZKSzVyPU[uNlc1OjhizszN NX\MV21sW0GQR1XS
NB6 NUPBRWh2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEWxN5dKSzVyPU[uNlk3OjJizszN M2TLdnNCVkeHUh?=
NALM-6 NXXs[GVnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml[5TWM2OD14LkOzNlMh|ryP Mm\JV2FPT0WU
NCI-H522 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4DCTGlEPTB;Nj6zN|MxPiEQvF2= M33iTXNCVkeHUh?=
MV-4-11 NFGxT5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnTzTWM2OD14LkO3NFc6KM7:TR?= MXvTRW5ITVJ?
LB2241-RCC M1XxXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYD1cYp3UUN3ME22MlM5PjZ5IN88US=> NFfsS3VUSU6JRWK=
NCI-H1417 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYDNRodTUUN3ME22MlQxQDR5IN88US=> NESy[G9USU6JRWK=
HT-1197 M370bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFTU[ItKSzVyPU[uOVcyOjJizszN NFy1UmFUSU6JRWK=
P30-OHK MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MorzTWM2OD14Lk[yO|ch|ryP NWSzc4dqW0GQR1XS
ALL-PO NVTITYZ5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn;DTWM2OD14LkexPVE3KM7:TR?= Mlq3V2FPT0WU
OVCAR-4 MlPQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlvJTWM2OD14Lke1OFA2KM7:TR?= MUPTRW5ITVJ?
HCC2157 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFjmWVBKSzVyPU[uO|c1PzVizszN NV:2e2FFW0GQR1XS
NCI-H838 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIGwbo1KSzVyPU[uPVY1QSEQvF2= NHS1d21USU6JRWK=
NCI-H1299 M2jvTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlfvTWM2OD14Lkm3NFkh|ryP NFfidWFUSU6JRWK=
SW954 MnnUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYjleFhlUUN3ME23MlIxODZ6IN88US=> M{T6RnNCVkeHUh?=
NCI-H441 MkfhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHfJUFVKSzVyPUeuN|QxPjVizszN MUXTRW5ITVJ?
SK-MEL-2 NXnVdmh4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1KzdWlEPTB;Nz60PFM4OyEQvF2= M1P1cXNCVkeHUh?=
KARPAS-45 NV30T2M{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF3peIJKSzVyPUeuOlU6OjlizszN MnfwV2FPT0WU
CAL-54 M4rO[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MY\JR|UxRTdwOEK5O|ch|ryP MWXTRW5ITVJ?
KYSE-180 M2jMUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2PneGlEPTB;Nz64PFk1OSEQvF2= MXXTRW5ITVJ?
NCI-H187 NIPxPYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1n2XGlEPTB;Nz65OVk1PyEQvF2= NUnqVFRqW0GQR1XS
RT-112 NILJSVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlnrTWM2OD16LkC5Olc4KM7:TR?= NFzFcnJUSU6JRWK=
NCI-H1437 NYHaV2d6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3TVe2lEPTB;OD6wPVc6PSEQvF2= NGPj[I1USU6JRWK=
SNU-449 NXezXVZ4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGq3O3VKSzVyPUiuNlgzPzJizszN NX;zN2lwW0GQR1XS
HCC1187 MmTFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEXtb5NKSzVyPUiuNlk{QTFizszN Ml61V2FPT0WU
NCI-H2030 NYrhZYtjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXPJR|UxRThwM{e3NVQh|ryP MYXTRW5ITVJ?
HuO-3N1 NU[4SmxNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHfZVI5KSzVyPUiuN|c5PDRizszN NYjKWoN{W0GQR1XS
COLO-792 NYnYT41lT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVnzb5RnUUN3ME24MlQyPTJ5IN88US=> MkP1V2FPT0WU
MIA-PaCa-2 Ml3FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkKxTWM2OD16Lki1OVA5KM7:TR?= MoX1V2FPT0WU
SK-N-FI NXn0bVNoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmHKTWM2OD17LkC0NlUh|ryP NHvaUmlUSU6JRWK=
MMAC-SF MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mlz0TWM2OD17LkC5O|UyKM7:TR?= NELwdpJUSU6JRWK=
NCI-H28 NXHUdFhYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXLHZoVkUUN3ME25MlExPDZ7IN88US=> NUnXUIg5W0GQR1XS
ETK-1 MoHkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmTQTWM2OD17LkK5PVc1KM7:TR?= MW\TRW5ITVJ?
NCI-H1993 M1ThU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2\OU2lEPTB;OT60OFI3OSEQvF2= NVjiO5dxW0GQR1XS
no-11 NHvXV3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2TMPWlEPTB;OT60O|EzKM7:TR?= M4PNcnNCVkeHUh?=
ChaGo-K-1 NWrFWGUxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVzxZ5RXUUN3ME25MlUyPTh|IN88US=> M4LxRXNCVkeHUh?=
NCCIT NHr2RopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVvJR|UxRTlwNUOxOlkh|ryP NX7BNIU5W0GQR1XS
SAS M1vFcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXfQWnJ{UUN3ME2xNE4zPDhizszN NUjBfHR7W0GQR1XS
A673 MlToS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVrufWdpUUN3ME2xNE4{PzB2IN88US=> MkPhV2FPT0WU
NCI-H1522 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFr4TIVKSzVyPUGwMlM4ODdizszN MmTkV2FPT0WU
NCI-H810 Mof1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmPpTWM2OD1zMD6zPVA4KM7:TR?= NV7lO5I2W0GQR1XS
IST-MES1 NYDuSWU3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4H3dGlEPTB;MUCuOFU3PCEQvF2= NEfGdHFUSU6JRWK=
GR-ST MlnIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlTtTWM2OD1zMD61NFI1KM7:TR?= NY\4WVZpW0GQR1XS
SUP-T1 NX\GPVh{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVzJR|UxRTFyLkezNVch|ryP M4H3d3NCVkeHUh?=
NB5 M136bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkTGTWM2OD1zMD65NFIzKM7:TR?= M3jmXnNCVkeHUh?=
MZ1-PC MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2D2R2lEPTB;MUCuPVU4OSEQvF2= MVTTRW5ITVJ?
SK-CO-1 NELJXZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnLzTWM2OD1zMD65PVMyKM7:TR?= MYrTRW5ITVJ?
Capan-2 M3\mOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlrOTWM2OD1zMT6zNVk5KM7:TR?= MmT1V2FPT0WU
697 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEe0d2NKSzVyPUGxMlY4PTdizszN NEjXd5pUSU6JRWK=
REH NHGwUlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYKxOHdKUUN3ME2xNU44PDVzIN88US=> NVTFUFB{W0GQR1XS
GI-1 MnnrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIrMV2RKSzVyPUGxMlg3OTVizszN NGPxPWlUSU6JRWK=
BB65-RCC NISzOHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{Xab2lEPTB;MUKuNFkyPiEQvF2= MVPTRW5ITVJ?
NCI-H1651 NF23R2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mne4TWM2OD1zMj6yOFc5KM7:TR?= NFP6emdUSU6JRWK=
NCI-H1618 NV7SWpJQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXjJR|UxRTF{LkO5O|Yh|ryP NEDBS49USU6JRWK=
NCI-H2081 NGn3[GdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mlj6TWM2OD1zMj62NVQyKM7:TR?= MX;TRW5ITVJ?
GCIY NXyxOmpST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3eyS2lEPTB;MUKuO|IyOyEQvF2= NHe5cVNUSU6JRWK=
NY M3jLOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mm\4TWM2OD1zMz6wOlQ{KM7:TR?= MWnTRW5ITVJ?
PANC-03-27 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXPReZQ4UUN3ME2xN{4xQDB5IN88US=> NWHvUXN6W0GQR1XS
BHY NVLwSpZET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlP2TWM2OD1zMz6yNVIyKM7:TR?= NFXxOnNUSU6JRWK=
SK-OV-3 M1TXdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGfaUIxKSzVyPUGzMlM4PjNizszN NE\WbVBUSU6JRWK=
5637 M{fKc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mk\aTWM2OD1zMz63O|U6KM7:TR?= MYDTRW5ITVJ?
LC-1F NVXUOIJGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWLJR|UxRTF2LkCzOVYh|ryP NYe4ZXhSW0GQR1XS
SNB75 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHTkPHJKSzVyPUG0MlA{QDNizszN NEjJTmJUSU6JRWK=
CHP-212 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3X6PWlEPTB;MUSuNFQ3PCEQvF2= MnLtV2FPT0WU
HT-1376 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3XaSGlEPTB;MUSuNVEzPiEQvF2= M13wR3NCVkeHUh?=
MONO-MAC-6 Mn61S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2ixdWlEPTB;MUSuNVUxOiEQvF2= NFrEe3lUSU6JRWK=
CA46 Ml;mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWHJU5Q2UUN3ME2xOE4yQDJ5IN88US=> NI\SNo1USU6JRWK=
SCC-15 NF3ob3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVj2TY5[UUN3ME2xOE42PTh|IN88US=> M1PN[XNCVkeHUh?=
ATN-1 NFO2Z3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVjFVpV1UUN3ME2xOE43PjJ5IN88US=> M{LsVXNCVkeHUh?=
NCI-H2405 MoW4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV\BfHJmUUN3ME2xOE45OTV5IN88US=> MnTPV2FPT0WU
NCI-H716 MlTXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFO3VpFKSzVyPUG0Mlg1QTNizszN MnrwV2FPT0WU
SW620 NWntfJRGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWPlU|FzUUN3ME2xOE46ODF2IN88US=> NEnrXnhUSU6JRWK=
NCI-H226 NF7vSFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVr0[W1UUUN3ME2xOE46ODh3IN88US=> MYjTRW5ITVJ?
SW962 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVjpdY9VUUN3ME2xOE46PDN{IN88US=> MWfTRW5ITVJ?
KYSE-150 MlK5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NITCWHNKSzVyPUG0Mlk2PSEQvF2= MnqzV2FPT0WU
OCUB-M MmnhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1r6d2lEPTB;MUSuPVg5OyEQvF2= NVXJ[VFzW0GQR1XS
ES7 NUHpd5ViT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUHJR|UxRTF3LkC5PFQh|ryP NGDqOm9USU6JRWK=
SW1463 M3uzb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFG0e|BKSzVyPUG1MlQzOjNizszN M4PDNHNCVkeHUh?=
CAKI-1 MmTpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{fWXWlEPTB;MUWuOVM1PiEQvF2= Mni2V2FPT0WU
MKN28 NF3YOVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUHJR|UxRTF3LkW0O|kh|ryP NVi4SYZoW0GQR1XS
SW13 NFLhV2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWTJR|UxRTF3Lk[xPEDPxE1? MVjTRW5ITVJ?
A3-KAW Ml;aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnvMTWM2OD1zNT65Olk4KM7:TR?= NEH1cZNUSU6JRWK=
LU-65 NWfWblA1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYTqUXRTUUN3ME2xOU46PzZ6IN88US=> NF7nT|NUSU6JRWK=
Calu-1 Mn72S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVHJR|UxRTF4LkCzOlgh|ryP NX;FcnZHW0GQR1XS
ST486 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlvYTWM2OD1zNj6wOFMyKM7:TR?= MYnTRW5ITVJ?
BB30-HNC NWHNWoN{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYPOOmV7UUN3ME2xOk4yOjR4IN88US=> NF3ZTItUSU6JRWK=
EGI-1 NGro[YpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWnJR|UxRTF4LkS0OkDPxE1? NV25[5hrW0GQR1XS
SH-4 NUPGTFJYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFfyU5dKSzVyPUG2MlQ4OzFizszN MXLTRW5ITVJ?
MN-60 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXj0V3k6UUN3ME2xO{4zOjl5IN88US=> MXvTRW5ITVJ?
MPP-89 NFvNV|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn;ZTWM2OD1zNz6yOFU6KM7:TR?= M1[3SHNCVkeHUh?=
A2780 M2\kXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkO2TWM2OD1zNz60NVM6KM7:TR?= NFvzWoFUSU6JRWK=
Daoy NE\PPHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEO3UWhKSzVyPUG3MlQ3QTVizszN M4\pPXNCVkeHUh?=
NCI-H2126 NWDURmIzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVjJR|UxRTF5LkS3O|Eh|ryP NEPHeGZUSU6JRWK=
NCI-H1563 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NU\OSJM{UUN3ME2xO{41QTF5IN88US=> MXnTRW5ITVJ?
8-MG-BA NVzDbopCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MU\JR|UxRTF5Lk[2OFgh|ryP NHeyUHRUSU6JRWK=
786-0 NImy[ZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{fNb2lEPTB;MUeuPFM2OyEQvF2= MWfTRW5ITVJ?
AM-38 NXTNNFRzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{XSSGlEPTB;MUeuPVMxPiEQvF2= MlHVV2FPT0WU
COLO-824 NHzTO5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NETzN|dKSzVyPUG4MlQ1OzZizszN MVfTRW5ITVJ?
SK-MEL-30 NVq1fFBzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYDJR|UxRTF6LkWwPFIh|ryP NWrTfJJzW0GQR1XS
CESS MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4r2XmlEPTB;MUiuO|YxQSEQvF2= NHr2UY1USU6JRWK=
BL-70 NXfZbYlrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1foTmlEPTB;MUiuPFE2PiEQvF2= MkHmV2FPT0WU
NCI-H2170 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUH3cHpLUUN3ME2xPE46OTd7IN88US=> MWnTRW5ITVJ?
HT-3 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkSxTWM2OD1zOD65PFMh|ryP M2XDeHNCVkeHUh?=
BOKU M1vxWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnXqTWM2OD1zOT6wN|gyKM7:TR?= M4TEfXNCVkeHUh?=
HPAF-II NGTMWndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIG3e3ZKSzVyPUG5MlMxOTVizszN MX;TRW5ITVJ?
KGN NEXnfYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXjJR|UxRTF7LkS3OlUh|ryP NFXF[pZUSU6JRWK=
MC-CAR NEi5codIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVHJR|UxRTF7Lk[zNVMh|ryP M4i4[HNCVkeHUh?=
BHT-101 Ml3US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{S5NWlEPTB;MUmuO|c4KM7:TR?= NGHWNZhUSU6JRWK=
SW1783 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn76TWM2OD1zOT63PFA3KM7:TR?= MoDqV2FPT0WU
KP-N-YN NHjQSVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVOyZZcxUUN3ME2yNE4xOjZ{IN88US=> NF2zfW9USU6JRWK=
LU-165 NIrYWJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWm1Rlc3UUN3ME2yNE42PTdzIN88US=> NHKxZlBUSU6JRWK=
GOTO NH7YWG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVvNSW1zUUN3ME2yNE43PDVzIN88US=> M3jDb3NCVkeHUh?=
EFM-19 MoLFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUXJR|UxRTJzLkC3NVYh|ryP Mlr3V2FPT0WU
CTV-1 M4XjNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmX5TWM2OD1{MT6xNFU1KM7:TR?= MULTRW5ITVJ?
HEL NGLkZYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX3JR|UxRTJzLkSyNVYh|ryP NXO3eYhqW0GQR1XS
SNU-C2B M{nTeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIDUfotKSzVyPUKxMlQzPiEQvF2= NXWxZZpZW0GQR1XS
ECC4 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3K0NGlEPTB;MkGuO|A4KM7:TR?= NFjKXHJUSU6JRWK=
NEC8 NFPzTGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1fNXGlEPTB;MkGuPFM3QCEQvF2= NXnGZnNNW0GQR1XS
KMOE-2 NYPXdIN6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWTJR|UxRTJzLki5NlEh|ryP NV;wcGVLW0GQR1XS
NCI-H524 NVXwdZhyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWrJR|UxRTJ{LkC4NFgh|ryP NUGyR2NwW0GQR1XS
WSU-NHL M4rK[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NELWcWxKSzVyPUKyMlE2PzdizszN M3PDNnNCVkeHUh?=
SF126 M3HPSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXnCNXNlUUN3ME2yNk4zPDZ7IN88US=> MUXTRW5ITVJ?
HOP-92 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlvrTWM2OD1{Mj6zNVY4KM7:TR?= NFH1e3JUSU6JRWK=
CTB-1 MlfUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnzRTWM2OD1{Mj60Olc4KM7:TR?= MUDTRW5ITVJ?
KYSE-270 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3GwfmlEPTB;MkKuPVM2PyEQvF2= MkG2V2FPT0WU
SK-MEL-24 M{PGNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFL0VmpKSzVyPUKzMlE5PyEQvF2= MVvTRW5ITVJ?
Calu-3 MoSzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHftZXpKSzVyPUKzMlIyOjhizszN NYfSPFRPW0GQR1XS
GAMG NEnteIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIH1TW1KSzVyPUKzMlI{PjdizszN NH7DRmhUSU6JRWK=
SW1573 NIHZbpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEnUOXhKSzVyPUKzMlc1OTVizszN NXK5[2pzW0GQR1XS
MHH-NB-11 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MY\JR|UxRTJ2LkCxPVQh|ryP NEj6[49USU6JRWK=
TK10 NUPMVWlbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVHJR|UxRTJ2LkWwNVMh|ryP NEnOWI1USU6JRWK=
LB373-MEL-D MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYPJR|UxRTJ2Lk[wOlQh|ryP MVfTRW5ITVJ?
KALS-1 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnL0TWM2OD1{ND63N|I4KM7:TR?= Mly4V2FPT0WU
HUTU-80 M{ntN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWjJR|UxRTJ3LkiwN|Ih|ryP NHnrS49USU6JRWK=
HuP-T3 M3[xXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWTlU|ROUUN3ME2yOk4yPjd2IN88US=> NVLy[XJGW0GQR1XS
OE19 NYG1c5lQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGm2fFJKSzVyPUK2MlIyPTNizszN MkezV2FPT0WU
J82 M3;jeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXzJR|UxRTJ4LkK0O|Eh|ryP Mn7zV2FPT0WU
DU-4475 NIfaTplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX3JR|UxRTJ4LkO4NVkh|ryP MYLTRW5ITVJ?
DMS-53 NV3QUFZPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEi1VpdKSzVyPUK2MlUyOzhizszN NWfjNHVKW0GQR1XS
COLO-741 MoP6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlLhTWM2OD1{Nj64N|Q1KM7:TR?= MnzxV2FPT0WU
SW48 NFrJdHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX3JR|UxRTJ4Lki4NkDPxE1? MU\TRW5ITVJ?
IGR-1 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVjJR|UxRTJ4LkmzN|Qh|ryP MXHTRW5ITVJ?
639-V MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGHDbHdKSzVyPUK3MlAzPDVizszN NUL3R3U{W0GQR1XS
LK-2 MmPtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYHJR|UxRTJ5LkSxOFEh|ryP MULTRW5ITVJ?
NCI-H2347 M4PkSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUiwS4pYUUN3ME2yO{46Pjl7IN88US=> MnPrV2FPT0WU
NCI-H2228 MnrjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1fLNWlEPTB;MkiuNFkxPSEQvF2= NHW0bJpUSU6JRWK=
LS-123 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYTpUIh1UUN3ME2yPE4yOjZ{IN88US=> NI\DN41USU6JRWK=
U031 MnjlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWHJR|UxRTJ6LkK1NkDPxE1? MYDTRW5ITVJ?
NCI-H1792 M3v0Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{H6SWlEPTB;MkiuOFczOSEQvF2= MmjRV2FPT0WU
NCI-H2087 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWfJR|UxRTJ6Lke1OVIh|ryP Mo\zV2FPT0WU
NCI-H2342 NUfRT4VyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NInOOFVKSzVyPUK5MlUzODhizszN MV\TRW5ITVJ?
SW626 NEDVTlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF\WS29KSzVyPUK5Mlc2PiEQvF2= M1LT[nNCVkeHUh?=
LB2518-MEL NX7DNZpwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmnoTWM2OD1{OT64NVUh|ryP NYXzUY5wW0GQR1XS
RXF393 Mkf4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWLJR|UxRTNyLkC5OVIh|ryP M1PrcnNCVkeHUh?=
LC4-1 NFfJNXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGjqPYJKSzVyPUOwMlMxQTJizszN MmnKV2FPT0WU
NCI-H1694 MljNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWPDdXc3UUN3ME2zNE43PjJ2IN88US=> M3PVWHNCVkeHUh?=
K5 NIPpdodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnXiTWM2OD1|MD65O|AzKM7:TR?= M3Kw[XNCVkeHUh?=
HDLM-2 MlLlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHLRSFRKSzVyPUOwMlk4OjVizszN MmfIV2FPT0WU
BCPAP NWT0d|Z5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFLSW5lKSzVyPUOxMlg{PzlizszN NWfWXHJFW0GQR1XS
BC-3 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{nhU2lEPTB;M{KuNVQxOyEQvF2= MmfHV2FPT0WU
LB996-RCC MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWjvXoF2UUN3ME2zNk4zOzV6IN88US=> NUTSZ4cxW0GQR1XS
NCI-H2009 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV;aWXRnUUN3ME2zNk41QThzIN88US=> MlvQV2FPT0WU
HTC-C3 MkO4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mnv5TWM2OD1|Mz63OVE6KM7:TR?= NXzCUGE3W0GQR1XS
LAMA-84 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVzJR|UxRTN2LkS0NFch|ryP MlrPV2FPT0WU
CCRF-CEM NWjZWnlMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NU\QPHFHUUN3ME2zOE42PzF3IN88US=> MnXCV2FPT0WU
AN3-CA M4q3U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnyyTWM2OD1|NT6wOVY5KM7:TR?= MoDSV2FPT0WU
NCI-H1734 M2XXbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV;JR|UxRTN3LkK1OlEh|ryP NV7DTI5iW0GQR1XS
Ca-Ski M2[we2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYnNW21tUUN3ME2zOU41OTBzIN88US=> NV7rN|ZNW0GQR1XS
U-266 NF;5TJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUXMU4tQUUN3ME2zOU43OTF2IN88US=> MV\TRW5ITVJ?
SBC-5 NIXacFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFu0e|VKSzVyPUO1Mlc4QDFizszN NWjwZmF4W0GQR1XS
GT3TKB NUPLd21IT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHywUmFKSzVyPUO3MlEyPSEQvF2= M33YXXNCVkeHUh?=
MDA-MB-175-VII MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGjEPHRKSzVyPUO3MlIzPDhizszN M1TqU3NCVkeHUh?=
PFSK-1 M33yU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYXNToUyUUN3ME2zO{4zPDN3IN88US=> NWG0NoR5W0GQR1XS
IMR-5 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MULJR|UxRTN5LkK0PFch|ryP M1HGWHNCVkeHUh?=
Daudi Ml\XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUDHXpc5UUN3ME2zO{4{PTl5IN88US=> NXm5OHZrW0GQR1XS
A498 M1Xoe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2\0UmlEPTB;M{euO|IyQCEQvF2= M3TxcXNCVkeHUh?=
SCC-4 MmfOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIrFcI5KSzVyPUO3Mlc5PDNizszN NHjhZlFUSU6JRWK=
COLO-680N M4[yXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVn6NmNpUUN3ME2zPE4zQDh3IN88US=> NI\DcWZUSU6JRWK=
SK-MES-1 NF7vPXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYfJR|UxRTN6LkOyNVUh|ryP MX\TRW5ITVJ?
SR M{TMO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mlm4TWM2OD1|OD61OFk2KM7:TR?= NXS5dotKW0GQR1XS
LNCaP-Clone-FGC M13uOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1nYV2lEPTB;M{iuOVY{PyEQvF2= M2XldHNCVkeHUh?=
SK-HEP-1 NWjjXlN7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{jkXGlEPTB;M{iuO|gzOiEQvF2= NF22SG5USU6JRWK=
BPH-1 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml3UTWM2OD1|OD64N|I6KM7:TR?= NWLKSVZGW0GQR1XS
NCI-H1755 M2TRV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVPJR|UxRTN7LkW4NVch|ryP NXv2RldsW0GQR1XS
LXF-289 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYDNRXU2UUN3ME2zPU45ODh2IN88US=> Mn20V2FPT0WU
SW1088 MkLQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVHJR|UxRTRyLkKxNFch|ryP M3jwN3NCVkeHUh?=
MOLT-4 Ml;XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M37OWGlEPTB;NECuNlkxOSEQvF2= M3TYfHNCVkeHUh?=
AsPC-1 NVrlPJAzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUj6UlZJUUN3ME20NE41PTh|IN88US=> MX7TRW5ITVJ?
HOP-62 Mn\SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFe2eXFKSzVyPUSwMlY2PjhizszN NH7aUWtUSU6JRWK=
A172 M{fLPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{D3SWlEPTB;NECuPFUyOSEQvF2= NIXzSo5USU6JRWK=
SN12C MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlHRTWM2OD12MD65N|g2KM7:TR?= MX3TRW5ITVJ?
MDA-MB-231 M3jjPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkD3TWM2OD12MD65PFk5KM7:TR?= M1LUZXNCVkeHUh?=
RPMI-2650 NI\D[3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUXYeVdiUUN3ME20NU4yPTl|IN88US=> M4L1bnNCVkeHUh?=
KYSE-140 M4LUZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1rPTmlEPTB;NEGuPFEzOyEQvF2= MkfTV2FPT0WU
KINGS-1 NXTTRZVoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX3aXmJZUUN3ME20Nk41Pjl5IN88US=> NFT1eFVUSU6JRWK=
HSC-3 M{jCWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFzyTYlKSzVyPUSyMlY3PjFizszN M{TtfHNCVkeHUh?=
PC-14 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYjJR|UxRTR|LkG4PFIh|ryP MmPKV2FPT0WU
COR-L105 NHrJe4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnXkTWM2OD12Mz62OVAzKM7:TR?= NIj6RmxUSU6JRWK=
BE-13 M{\ES2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEOwd3RKSzVyPUS0MlI{PzFizszN M2jofHNCVkeHUh?=
NCI-H661 MnjCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGf0PIpKSzVyPUS0MlI6PThizszN NUG2eVhjW0GQR1XS
IST-MEL1 NI\kbXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH;kRXRKSzVyPUS0MlM2QTlizszN Ml\tV2FPT0WU
HCC1806 M1rZS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFHWenlKSzVyPUS0MlU5PzNizszN MnHyV2FPT0WU
COLO-800 MlO3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWHZdVhVUUN3ME20OE45PDV|IN88US=> MV\TRW5ITVJ?
IST-SL2 NFTRR41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3XwW2lEPTB;NEWuNVI1PyEQvF2= NF7lZXlUSU6JRWK=
8305C NYnBWWZST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1;Q[GlEPTB;NEWuN|A6KM7:TR?= MoTmV2FPT0WU
UACC-62 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWTWZXdvUUN3ME20Ok4zQDd3IN88US=> MVHTRW5ITVJ?
COR-L23 NHHadGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MonNTWM2OD12Nz6xPVkh|ryP NVnZNJA2W0GQR1XS
EFE-184 MmLOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2e2OmlEPTB;NEeuN|g5KM7:TR?= MmOyV2FPT0WU
DMS-114 MmXYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2XNOGlEPTB;NEeuOFE1QSEQvF2= M37DenNCVkeHUh?=
KYSE-520 NVTINZlFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{fSNmlEPTB;NEiuOVMyPSEQvF2= NI\4cGtUSU6JRWK=
SNG-M MmXWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYftbHdvUUN3ME20PU41OzRizszN MUTTRW5ITVJ?
A2058 M{W5dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGOzemlKSzVyPUS5MlQ5QDVizszN MorCV2FPT0WU

... Click to View More Cell Line Experimental Data
Assay
Methods Test Index PMID
Western blot
p-EGFR / EGFR / p-IGF1R / IGF1R / p-IRS1 / IRS1 / p-ERK / ERK / p-AKT / AKT; 

PubMed: 26052929     


Effects of linsitinib on EGFR and IGF1R Signaling Pathways. H1975, AR1, AR2 and AR3 cells were treated with control DMSO or linsitinib (2 and 5 μM) for 24 hours. Cell lysates were subjected to Western blot analysis. IGF1R-IRS-1-AKT phosphorylation was effectively inhibited by linsitinib in afatinib resistance cells whereas IRS-1-AKT phosphorylation was up-regulated by linsitinib in H1975 parental cells.

p-IGF1R / IGF1R / p-mTOR / mTOR ; 

PubMed: 28440057     


Linsitinib inhibits the activation of ERK and PI3K pathways. After treatment of Linsitinib at 0.1 or 1.0 μmol/L for 72 h, the phosphorylation of insulin‐like growth factor‐1 receptor (IGF‐1R), ERK1/2, and AKT/mTOR pathways were analyzed in TE‐13, TE‐1, and KYSE‐510 cell lines by western blot.

cleaved caspase-3 / cleaved PARP; 

PubMed: 28440057     


Reduced apoptosis in Linsitinib-resistant esophageal squamous cell carcinoma cells. After treatment of Linsitinib at 0.1 or 1.0 μmol/L for 72 h, cleaved PARP and activated Caspase‐3 were examined in TE-13, TE-1, and KYSE-510 cells by western blot. Tubulin was used as a loading control.

pSrc(Y416) / Src; 

PubMed: 26515601     


A549, H226Br, and H1975 cells were treated with 1 or 2 μM linsitinib (diluted in RPMI 1640 medium containing 10% FBS) for 12 or 24 h. Before harvest, cells were further stimulated with 10% FBS for 20 min. Cells were lysed with modified RIPA buffer and the protein expression was determined by Western blot analysis.

p-STAT3(Y705) / STAT3 ; 

PubMed: 26041671     


H226B and H460 cells were subject to daily treatment with linsitinib (1 μM) for 1-5 days.

pS6 / S6; 

PubMed: 21257723     


Western blot of NCI-H292 cells following 30 minutes of exposure to OSI-906 shows target inhibition of pIGF-1R and pIR at all doses as well as inhibition of downstream targets pAKT and pS6.

26052929 28440057 26515601 26041671 21257723
Immunofluorescence
FoxO1; 

PubMed: 27535223     


After starvation, control or βIRKO β-cell lines were treated with insulin (10 nm) in combination with high glucose (450 mg/dL), in the presence or absence of PI3K inhibitor LY294002, insulin receptor, and IGF1 receptor dual inhibitor OSI-906, Akt inhibitor MK2206, or MEK1/2 inhibitor U0126 for 30 min.  A, representative pictures of β-cells immunostained for FoxO1 (red) and DAPI (blue). The scale bar indicates 20 μm.

27535223
Growth inhibition assay
Cell viability; 

PubMed: 26136493     


InsR/IGF1R dual inhibitors, OSI-906 and BMS-754807, dose-dependently inhibited T4105 viability.

26136493
体内研究 OSI-906 作用于IGF-IR驱动的移植瘤鼠模型，抑制肿瘤生长，按 75 mg / kg剂量处理，导致100% TGI和 55% 衰退，按25 mg/kg剂量处理，导致 60% TGI，没有衰退。OSI-906处理犬，大鼠和小鼠，诱导不同的消除半衰期，消除半衰期分别为1.18 小时, 2.64小时 和2.14小时。OSI-906按不同剂量单独处理给药雌性Sprague-Dawley 大鼠和雌性CD-1小鼠，每天一次，Vmax值与OSI-906 剂量不成比例。OSI-906 按 25 mg/kg剂量处理12天，提高血糖值。OSI-906按75 mg/kg 剂量单独处理IGF-IR-驱动的人全长人类IGF-IR (LISN)移植鼠模型，在4 和24小时间最大程度抑制IGF-IR磷酸化(80%)，血浆药物浓度为26.6-4.77 μM。[1] OSI-906 按60 mg/kg剂量单独作用于NCI-H292 移植鼠，处理2，4，24小时，抑制糖吸收。OSI-906 作用于NCI-H292移植鼠模型，抑制肿瘤生长。[2]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验：[1]
- 合并

蛋白激酶生化实验:

通过以ELISA为基础的检测法(IGF-IR, IR, EGFR 和 KDR)或使用100 µM ATP的放射检测法进行蛋白激酶检测实验。在内部ELISA检测实验中，使用聚 (Glu:Tyr)作为底物，结合到96孔实验板表面，使用辣根过氧化物酶标记的自磷酸化抗体测定磷酸化。使用ABTS作为过氧化物酶底物，通过在405/490 nm处测量吸光度而测定结合的抗体。所有实验使用纯化的重组激酶催化域。在昆虫细胞中，人类IGF-IR或EGFR的重组酶表达作为NH2-末端谷胱甘肽S-转移酶融合蛋白，且在内部纯化。通过抑制百分数对log10药品浓度的S型剂量-反应曲线测定IC50值。进行内部实验需重复进行实验，除非另有说明，取三次测量的最小值。
细胞实验：[1]
- 合并
  • Cell lines: MCF7, NCI-H292, Colo-205, HT29, H358, H1703, BxPC3, A673, SW620, DU4475, HepG2 和Hepa-1, RKO 3T3/hulGF-IR, H292 细胞
  • Concentrations: 0.02-0.8 μM
  • Incubation Time: 3天
  • Method: 为了测定细胞增殖，细胞接种在含FCS 10%的合适培养基上，在不同浓度OSI-906存在时，温育3天。通过细胞内ATP含量的荧光量化，使用CellTiterGlo测定抑制细胞生长的情况。数据作为衡量最大增殖的一部分，通过在不同浓度 OSI-906存在时的细胞密度除以对照组（只用DMSO处理）细胞密度。
    (Only for Reference)
动物实验：[1]
- 合并
  • Animal Models: IGF-IR驱动的全长人类IGF-IR (LISN) 移植小鼠模型
  • Formulation: 25 mM 酒石酸
  • Dosages: 25 mg/kg和75 mg/kg
  • Administration: 口服处理，每天一次，持续14天
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 84 mg/mL (199.29 mM)
Water Insoluble
Ethanol Insoluble
体内 从左到右依次将纯溶剂加入产品，现配现用(数据来自Selleck实验检测而非文献)：
5%DMSO+40%PEG300+5%Tween80+50%ddH2O
 6.25mg/mL

* 溶解度检测是由Selleck技术部门检测的，可能会和文献中提供的溶解度有所差异，这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 421.49
化学式

C26H23N5O
CAS号 867160-71-2
储存条件 粉状
溶于溶剂
别名 N/A

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系，公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液，使用的计算公式为：

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量：

总分子量：g/mol

注：化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT02546544 Completed Drug: Linsitinib Relapsed Ewing Sarcoma|Refractory Ewing Sarcoma University of Oxford|European Organisation for Research and Treatment of Cancer - EORTC|European Commission|Astellas Pharma Inc|Oxford University Hospitals NHS Trust March 2014 Phase 2
NCT01672736 Terminated Drug: ASP7487 Velcade Dexamethasone Multiple Myeloma University Health Network Toronto|Multiple Myeloma Research Consortium|Astellas Pharma Inc September 2012 Phase 1|Phase 2
NCT01529684 Completed Drug: radio-labeled OSI-906|Drug: OSI-906 Advanced Solid Tumors|Pharmacokinetics of 14C-OSI-906 Astellas Pharma Global Development Inc.|Astellas Pharma Inc March 19 2012 Phase 1
NCT01221077 Completed Drug: OSI-906|Drug: Erlotinib|Drug: Placebo NSCLC|Non Small Cell Lung Cancer Astellas Pharma Inc April 8 2011 Phase 2

技术支持

在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题，请给我们留言。

  • * 必填项

常见问题及建议解决方法

  • 问题 1：

    Does the inhibitor dissolve in the vehicle (30% PEG400/0.5%Tween 80/5% propylene glycol) or is it a suspension?

  • 回答：

    OSI-906 in 30% PEG400/0.5%Tween 80/5% propylene glycol is a suspension.

Selleck产品目录册

IGF-1R Signaling Pathway Map

IGF-1R Inhibitors with Unique Features

  • 泛IGF-1R抑制剂

    GSK1904529A : Dual IGF-1R/IR inhibitor, IC50=27 nM/25 nM.

  • 活性最高的IGF-1R抑制剂

    BMS-754807 : IGF-1R, IC50=1.8 nM; InsR, IC50=1.7 nM.

  • 用于临床的IGF-1R抑制剂

    BMS-754807 : Phase II for Breast Cancer.

  • 最新的IGF-1R抑制剂

    PQ 401 : Inhibitor of autophosphorylation of IGF-1R domain with IC50 of <1 μM.

相关IGF-1R产品

  • Picropodophyllin (PPP) New

    Picropodophyllin (PPP)是一种选择性IGF-1R抑制剂，IC50为1 nM。它对IGF-IR具有高选择性，对IR的酪氨酸磷酸化或FGF-R、PDGF-R、EGF-R没有抑制作用。

  • Erlotinib New

    Erlotinib 是一种EGFR抑制剂，IC50 为 2 nM，对EGFR的敏感性比对人c-Src 或 v-Ab高1000多倍。

  • Bemcentinib（R428) New

    R428 (BGB324)是一种Axl抑制剂，IC50为14 nM，作用于Axl比作用于Abl选择性高100倍以上。作用于Axl选择性也比作用于Mer和Tyro3(高50到100倍)及InsR， EGFR， HER2，和PDGFRβ(高100倍以上)高。

  • BMS-536924

    BMS-536924是一种ATP竞争性的IGF-1R抑制剂，IC50为100 nM，对Mek， Fak，和Lck也具有适中的抑制活性，但对Akt1，和MAPK1/2几乎无抑制活性。

  • NVP-AEW541

    NVP-AEW541是一种有效的IGF-1R/InsR抑制剂，在无细胞试验中IC50为150 nM/140 nM，在细胞试验中对IGF-1R具有较高的作用和选择性。

  • NVP-ADW742

    NVP-ADW742是一种IGF-1R抑制剂，IC50为0.17 μM，作用于IGF-1R比作用于InsR效果强16倍以上；对HER2， PDGFR， VEGFR-2， Bcr-Abl和c-Kit几乎没有活性。

  • GSK1904529A

    GSK1904529A是一种选择性的IGF-1R和IR抑制剂，无细胞试验中IC50分别为27 nM和25 nM，作用于IGF-1R/InsR比作用于Akt1/2/， Aurora A/B，B-Raf， CDK2， EGFR等选择性高100倍以上。

  • BMS-754807

    BMS-754807是一种有效的IGF-1R/InsR可逆性抑制剂，在无细胞试验中IC50为1.8 nM/1.7 nM，对Met，Aurora A/B，TrkA/B和Ron作用稍弱，对Flt3， Lck，MK2，PKA，PKC等几乎没有抑制活性。Phase 2。

    Features:胰岛素样生长因子-1R/IR家族激酶的多重抑制剂

  • AG-1024

    AG-1024 抑制IGF-1R自磷酸化，IC50为7 μM，对IR作用效果稍弱，IC50为57 μM，且特异性区分InsR和IGF-1R（相比于其他酪氨酸磷酸化抑制剂）。

  • PQ 401

    PQ 401抑制IGF-1R区域自磷酸化，IC50为低于1 μM。

Tags: 购买Linsitinib (OSI-906) | Linsitinib (OSI-906)供应商 | 采购Linsitinib (OSI-906) | Linsitinib (OSI-906)价格 | Linsitinib (OSI-906)生产 | 订购Linsitinib (OSI-906) | Linsitinib (OSI-906)代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID